HeartFlow(HTFL.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
HeartFlow
HTFL.US
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient’s heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart’s arteries. The company’s platform provides insights on blood flow, stenosis, and plaque volume and composition by overcoming the limitations of traditional non-invasive imaging tests. The company was founded in 2007 and is headquartered in Mountain View, California.
61.41 B
HTFL.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Heartflow, Inc.'s Lock-Up Period Will Expire on February 4th (NASDAQ:HTFL)

    Heartflow, Inc. (NASDAQ:HTFL) will see its lock-up period expire on February 4th, allowing insiders to trade their shares. The company issued 16,666,667 shares during its IPO on August 8th, raising $316.67 million at an initial price of $19.00. Analysts have mixed ratings on the stock, with a consensus rating of "Hold" and a price target of $38.60. Recent insider trading includes Director Jeffrey C. Lightcap purchasing 40,000 shares. Heartflow specializes in non-invasive diagnostic solutions for coronary artery disease.

    Market Beat·
    US
    HTFL
    -0.03%
    Market Beat·
    US
    HTFL
    -0.03%

    Baillie Gifford & Co. Takes $101.18 Million Position in Heartflow, Inc. $HTFL

    Baillie Gifford & Co. has acquired a new position in Heartflow, Inc. (NASDAQ:HTFL), purchasing 3,005,998 shares valued at approximately $101.18 million during Q3. This investment represents 3.60% ownership in the company. Other hedge funds have also invested in Heartflow. Analysts have mixed ratings on the stock, with a consensus price target of $38.60. Heartflow's shares opened at $32.16, with a market cap of $2.74 billion. The company specializes in non-invasive diagnostic solutions for coronary artery disease.

    Market Beat·
    US
    HTFL
    -0.03%
    Market Beat·
    US
    HTFL
    -0.03%

    AI Diagnostics: The End of the High-Cost Imaging Era

    The AI medical imaging market is projected to grow at 25.8% annually through 2034, shifting from expensive hardware to software-defined solutions. Companies like VentriPoint Diagnostics and Heartflow are leading this transition, focusing on decentralized diagnostics. A significant catalyst is the July 2026 launch of CMS’s ACCESS Model, which will provide reimbursement for AI platforms that demonstrate cost-effectiveness. VentriPoint is enhancing its financial modeling with Summit Sciences to show economic value, while also expanding access to advanced cardiac imaging in underserved communities. Heartflow has gained coverage from Aetna, furthering access to its AI-driven technology.

    fidelity·
    US
    HTFL
    -0.03%
    fidelity·
    US
    HTFL
    -0.03%

    HeartFlow updates investors, emphasizing AI coronary diagnostics

    HeartFlow, Inc. (HTFL) updated investors on its leadership in AI-driven coronary artery disease diagnostics, highlighting strong commercial traction and a revenue of $162 million. The company emphasizes the potential of AI-enabled imaging as a new standard of care. Despite a positive analyst rating of Buy with a $40 price target, Spark's AI Analyst rates HTFL as Neutral due to financial instability and a bearish trend. HeartFlow targets a $5 billion U.S. market, with significant growth potential and risks from competition and regulation.

    Tip Ranks·
    US
    HTFL
    -0.03%
    Tip Ranks·
    US
    HTFL
    -0.03%

    Heartflow Inc. showcases AI-driven CAD care advancements and growth strategy in new investor presentation

    Heartflow Inc. has unveiled an investor presentation detailing its advancements in AI technology for coronary artery disease (CAD). The presentation emphasizes the company's growth in the U.S. market, with an increase in active physician customers and improved non-GAAP gross margins. Heartflow's platform is clinically proven for CAD detection and management, focusing on symptomatic patients while planning to expand into asymptomatic markets. The company anticipates growth through an expanded U.S. market and new product developments for plaque analysis and disease staging.

    Reuters·
    US
    HTFL
    -0.03%
    Reuters·
    US
    HTFL
    -0.03%
    © 2026 Longbridge｜Disclaimer